FDA Approves New Parkinson's Drug Developed from University of Virginia Research
What happened
The U.S. Food and Drug Administration approved tavapadon, a new treatment for Parkinson’s disease sold under the brand name Juvmo. This once-daily pill for adults was developed from research conducted at the University of Virginia. Richard Mailman, a professor at the University of Virginia School of Medicine, pioneered the research behind Juvmo.
From wset.com
Why it matters
The approval introduces a new therapeutic option for Parkinson’s disease, which affects the market for neurological treatments. The drug was developed to address limitations associated with levodopa, the longstanding standard treatment for the condition.
From wset.com
Who's involved
- Richard MailmanPioneered the research that led to the development of Juvmo
- University of VirginiaConducted the research that resulted in the FDA approval of the new drug
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Richard MailmanSpeculative
Richard Mailman could see increased funding access or commercialization opportunities for his pioneering research.
Keep exploring
The entities involved
-
University of Virginia
public university in Charlottesville, Virginia